USANA Health Sciences (NYSE:USNA) Earns Hold Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of USANA Health Sciences (NYSE:USNA) in a report released on Thursday morning, 24/7 WallStreet reports. The firm issued a hold rating and a $65.00 price objective on the stock.

USNA has been the subject of a number of other reports. TheStreet cut shares of USANA Health Sciences from a b- rating to a c+ rating in a report on Thursday, July 11th. ValuEngine upgraded shares of USANA Health Sciences from a sell rating to a hold rating in a report on Thursday, August 1st. Pivotal Research restated a buy rating on shares of USANA Health Sciences in a report on Wednesday, July 24th. Finally, Sidoti downgraded shares of USANA Health Sciences from a buy rating to a neutral rating and set a $70.00 price target for the company. in a research report on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $70.00.

USANA Health Sciences stock opened at $64.29 on Thursday. The firm has a 50 day simple moving average of $64.96 and a 200-day simple moving average of $80.58. The stock has a market capitalization of $1.50 billion, a PE ratio of 12.46 and a beta of 0.44. USANA Health Sciences has a 12-month low of $58.30 and a 12-month high of $134.65.



USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $0.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.93 by ($0.02). The company had revenue of $256.00 million during the quarter, compared to the consensus estimate of $254.66 million. USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. The company’s revenue was down 15.1% on a year-over-year basis. During the same quarter last year, the business earned $1.36 earnings per share. As a group, equities research analysts forecast that USANA Health Sciences will post 3.9 earnings per share for the current year.

Several large investors have recently modified their holdings of USNA. Tower Research Capital LLC TRC purchased a new stake in shares of USANA Health Sciences in the 2nd quarter valued at approximately $27,000. Royce & Associates LP lifted its position in USANA Health Sciences by 66.4% in the 1st quarter. Royce & Associates LP now owns 381 shares of the company’s stock worth $32,000 after buying an additional 152 shares in the last quarter. LS Investment Advisors LLC purchased a new stake in USANA Health Sciences in the 2nd quarter worth approximately $32,000. Advisory Services Network LLC purchased a new stake in USANA Health Sciences in the 2nd quarter worth approximately $65,000. Finally, NEXT Financial Group Inc purchased a new stake in USANA Health Sciences in the 2nd quarter worth approximately $79,000. Institutional investors and hedge funds own 66.39% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Read More: Gap Down Stocks

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.